参考文献:1. Schmidt, M, Bastians, H (2007) Mitotic drug targets and the development of novel anti-mitotic anticancer drugs. Drug Resist Updat 10: pp. 162-181 CrossRef 2. Morris, PG, Fornier, MN (2008) Microtubule active agents: beyond the taxane frontier. Clin Cancer Res 14: pp. 7167-7172 8/1078-0432.CCR-08-0169" target="_blank" title="It opens in new window">CrossRef 3. Janssen, A, Medema, RH (2011) Mitosis as an anti-cancer target. Oncogene 30: pp. 2799-2809 8/onc.2011.30" target="_blank" title="It opens in new window">CrossRef 4. Sarli, V, Giannes, A (2008) Targeting the kinesin spindle protein: basic principles and clinical implications. Clin Cancer Res 14: pp. 7583-7587 8/1078-0432.CCR-08-0120" target="_blank" title="It opens in new window">CrossRef 5. Miglarese, MR, Carlson, RO (2006) Development of new cancer therapeutic agents targeting mitosis. Expert Opin Investig Drugs 15: pp. 1411-1425 84.15.11.1411" target="_blank" title="It opens in new window">CrossRef 6. Drummond, DR (2011) Regulation of microtubule dynamics by kinesins. Semin Cell Dev Biol 22: pp. 927-934 CrossRef 7. Vale, RD, Milligan, RA (2000) The way things move: looking under the hood of molecular motor proteins. Science 288: pp. 88-95 88.5463.88" target="_blank" title="It opens in new window">CrossRef 8. Blangy, A, Lane, HA, d鈥橦茅rin, P, Harper, M, Kress, M, Nigg, EA (1995) Phosphorylation by p34cdc2 regulates spindle association of human Eg5, a kinesin-related motor essential for bipolar spindle formation in vivo. Cell 83: pp. 1159-1169 8674(95)90142-6" target="_blank" title="It opens in new window">CrossRef 9. Stern, BM, Murray, AW (2001) Lack of tension at kinetochores activates the spindle checkpoint in budding yeast. Curr Biol 11: pp. 1462-1467 822(01)00451-1" target="_blank" title="It opens in new window">CrossRef 10. Vijapurkar, U, Wang, W, Herbst, R (2007) Potentiation of kinesin spindle protein inhibitor-induced cell death by modulation of mitochondrial and death receptor apoptotic pathways. Cancer Res 67: pp. 237-245 8/0008-5472.CAN-06-2406" target="_blank" title="It opens in new window">CrossRef 11. Wojcik, EJ, Buckley, RS, Richard, J, Liu, L, Huckaba, TM, Kim, S (2013) Kinesin-5: cross-bridging mechanism to targeted clinical therapy. Gene 531: pp. 133-149 8.004" target="_blank" title="It opens in new window">CrossRef 12. Sakowicz, R, Finer, JT, Beraud, C, Crompton, A, Lewis, E, Fritsch, A (2004) Antitumor activity of a kinesin inhibitor. Cancer Res 64: pp. 3276-280 8/0008-5472.CAN-03-3839" target="_blank" title="It opens in new window">CrossRef 13. Huszar, D, Theoclitou, ME, Skolnik, J, Herbst, R (2009) Kinesin motor proteins as targets for cancer therapy. Cancer Metastasis Rev 28: pp. 197-208 85-8" target="_blank" title="It opens in new window">CrossRef 14. El-Nassan, HB (2013) Advances in the discovery of kinesin spindle protein (Eg5) inhibitors as antitumor agents. Eur J Med Chem 62: pp. 614-631 CrossRef 15. Woessner, R, Tunquist, B, Lemieux, C, Chlipala, E, Jackinsky, S, Dewolf, W (2009) ARRY-520, a novel KSP inhibitor with potent activity in hematological and taxane-resistant tumor models. Anticancer Res 29: pp. 4373-4380 16. Woessner, RD, Corrette, C, Allen, S, Hans, J, Zhao, Q, Aicher, T (2007) ARRY-520, a KSP inhibitor with efficacy and pharmacodynamic activity in animal models of solid tumors. Proc Am Assoc Cancer Res 48: pp. 1433 17. Derenne, S, Monia, B, Dean, NM, Taylor, JK, Rapp, MJ, Harousseau, JL (2002) Antisense strategy shows that Mcl-1 rather than Bcl-2 or Bcl-x(L) is an essential survival protein of human myeloma cells. Blood 100: pp. 194-199 82/blood.V100.1.194" target="_blank" title="It opens in new window">CrossRef 18. Opferman, JT, Letai, A, Beard, C, Sorcinelli, MD, Ong, CC, Korsmeyer, SJ (2003) Development and maintenance of B and T lymphocytes requires antiapoptotic MCL-1. Nature 426: pp. 671-676 8/nature02067" target="_blank" title="It opens in new window">CrossRef 19. Opferman, JT, Iwasaki, H, Ong, CC, Suh, H, Mizuno, S, Akashi, K (2005) Obligate role of anti-apoptotic MCL-1 in the survival of hematopoietic stem cells. Science 307: pp. 1101-1104 CrossRef 20. Zhang, B, Gojo, I, Fenton, RG (2002) Myeloid cell factor-1 is a critical survival factor for multiple myeloma. Blood 99: pp. 1885-1893 82/blood.V99.6.1885" target="_blank" title="It opens in new window">CrossRef 21. Tunquist, BJ, Woessner, RD, Walker, DH (2010) Mcl-1 stability determines mitotic cell fate of human multiple myeloma tumor cells treated with the kinesin spindle protein inhibitor ARRY-520. Mol Cancer Ther 9: pp. 2046-2056 8/1535-7163.MCT-10-0033" target="_blank" title="It opens in new window">CrossRef 22. Lonial, S, Shah, JJ, Zonder, J, Bensinger, WI, Cohen, AD, Kaufman, JL (2013) Prolonged survival and improved response rates with ARRY-520 in relapsed/refractory multiple myeloma (RRMM) patients with low 伪-1 acid glycoprotein (AAG) levels: results from a Phase 2 study. Blood 122: pp. 285 82/blood-2013-09-522409" target="_blank" title="It opens in new window">CrossRef 23. Shah, JJ, Feng, L, Thomas, SK, Weber, DM, Wang, M, Hilder, B (2013) Phase 1 Study of the novel kinesin spindle protein inhibitor ARRY-520鈥?鈥塩arfilzomib (Car) in patients with relapsed and/or refractory multiple myeloma (RRMM). Blood 122: pp. 1982 24. Chari, A, Htut, M, Zonder, J, Fay, JW, Jakubowiak, AJ, Harrison, B (2013) A Phase 1 study of ARRY-520 with bortezomib (BTZ) and dexamethasone (dex) in relapsed or refractory multiple myeloma (RRMM). Blood 122: pp. 1938 25. Chari A, Htut M, Zonder J, Fay JW, Jakubowiak AJ, Harrison B et al. (2014) Phase 1 study of filanesib (ARRY-520) with bortezomib (BTZ) and dexamethasone (dex) in relapsed or refractory multiple myeloma (RRMM). Presented at the 19th Congress of European Hematology Association (EHA), 06 June 2014, Milan, Italy. P370 (abstract)
刊物类别:Medicine
刊物主题:Medicine & Public Health Oncology Pharmacology and Toxicology